POXEL SA (Euronext – POXEL – FR0012432516), a biopharmaceutical company focused on developing innovative therapies for metabolic disorders such as type 2 diabetes and non-alcoholic steatohepatitis (NASH), today announced that it will attend upcoming virtual investor conferences in June 2021. Thomas Kuhn, CEO, will introduce the company and the members of the Poxel management team will be available for virtual one-on-one meetings.
Jefferies Global Healthcare Conference
Date: June 1st to 4th
Smallpox presentation on Tuesday, June 1, from 11:00 a.m. to 11:25 p.m. ET.
JMP Securities Conference
Date: 16th-17th centuries June
Smallpox presentation on Thursday, June 17, 10:30 am to 10:55 am ET.
Raymond James Human Health Innovations Conference
Date: June 21-23
Smallpox presentation on Tuesday, June 22nd, 8:40 am to 9:10 am ET.
About Poxel SA
Poxel is a dynamic biopharmaceutical company that uses its extensive know-how to develop innovative drugs for metabolic diseases with a focus on type 2 diabetes and non-alcoholic steatohepatitis (NASH) and selected rare hereditary diseases including adrenoleukodystrophy. The company is currently promoting three drug candidates in its mid- to late-stage pipeline. There are several earlier options as well. Imeglimin, Poxel’s premium lead product, targets mitochondrial dysfunction. Poxel has a strategic partnership with Sumitomo Dainippon Pharma for Imeglimin in Japan, China, South Korea, Taiwan and nine other Southeast Asian countries. A Japanese New Drug Application (J-NDA) is currently under review by the Pharmaceuticals and Medical Devices Agency (PMDA) for approval to manufacture and commercialize imeglimin for the treatment of type 2 diabetes. Upon successful completion of a Phase 2a proof-of-concept study for the treatment of NASH that met its primary endpoint and study objectives for PXL770, a world-class direct adenosine monophosphate activated protein kinase (AMPK) activator, Poxel plans to PXL770 as well have the potential to treat additional metabolic disorders. PXL065 (deuterium-stabilized R-pioglitazone), an MPC inhibitor, is in an optimized phase 2 study for the treatment of NASH. Poxel has additional early-stage programs of its AMPK activator and deuterated TZD platforms that target chronic and rare metabolic diseases. The company intends to generate further growth through strategic partnerships and pipeline development. Poxel is listed on Euronext Paris and is headquartered in Lyon, France with offices in Boston, MA and Tokyo, Japan. Further information is available at: www.poxelpharma.com
The story goes on
In connection with the COVID-19 outbreak, which was declared a pandemic by the World Health Organization (WHO) on March 12, 2020, the company is regularly reviewing the impact of the outbreak on its business.
As of the date of this press release, based on publicly available information, the company has not identified any material adverse effects on its business from the unresolved COVID-19 pandemic. However, the company believes that the COVID-19 pandemic could have other material adverse effects on its business. The global impact of COVID-19 can particularly affect the company’s internal organization and efficiency, especially in countries where it operates and where authorities are taking containment measures. In addition, COVID-19 can affect market conditions and the company’s ability to raise additional funding or enter into partnerships. In particular, there may be delays in the delivery of medicines or drugs, in the initiation or timing of the results of preclinical and / or clinical studies, and delays related to the responsiveness of regulators that could potentially impact the Company’s development programs and partner programs. The company will continue to actively monitor the situation.
All statements in this press release, other than historical facts, about future events are (i) subject to change without notice and (ii) factors over which the company has no control. These statements may contain, without limitation, any statements that are preceded by words such as “aim,” “believe,” “expect,” “aim,” “intend,” “may,” “anticipate,” “estimate”, followed by or “” plan “,” project “,” will “,” may “,” likely “,” should “,” would “,” could “and other words and expressions with similar meanings or negatives. Forward-looking statements are subject to inherent risks and Uncertainties that are beyond the control of the company and that could cause actual results or performance to differ materially from the expected results or performance expressed or implied by such forward-looking statements.
View source version on businesswire.com: https://www.businesswire.com/news/home/20210519005494/de/
contacts
Poxel SA
Catherine David
Investor Relations & Communication Manager
[email protected]
+33 7 64 57 61 78
Investor Relations / Media – EU / USA
Trophic communication
Stephanie May or Valeria Fisher
[email protected]
+49 171 185 56 82 or +49 175 804 1816
Investor Relations / Media – France
NewCap
Emmanuel Huynh or Arthur Rouillé
[email protected]
+33 1 44 71 94 94
